🇺🇸 BMRN — BioMarin Pharmaceutical Inc.

Salud Compra
← Volver

Precio actual

56,03 USD

Máx. histórico

149,13

4127 días

Caída desde máximo

-62,43%

Rango 52 semanas

49,26 – 70,98

Variación hoy

-0,16%

Cierre anterior

56,12

Rango de hoy

55,00 – 56,08

Volumen hoy

2.733.184

Peor caída histórica

-90,58%

01/03/2000 → 27/08/2002

Recuperado en 1960 días

Volatilidad anualizada ⓘ

49,10%

Información
Nombre completo
BioMarin Pharmaceutical Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
3.221
PER ⓘ
150,43 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
91,04 USD (puede no estar actualizado)
Primera cotización
26/07/1999
Precio actualizado
hace 8 horas
Sobre la empresa

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
09/07/2015 139,58 140,94 137,92 140,13 +1,85% 2,16% 1.286.300
08/07/2015 138,84 139,01 136,50 137,59 -1,57% 1,81% 1.071.300
07/07/2015 140,39 141,00 137,00 139,79 -0,22% 2,85% 1.420.300
06/07/2015 136,07 140,30 135,52 140,10 +2,38% 3,51% 1.695.200
02/07/2015 136,37 136,97 135,09 136,84 +0,08% 1,38% 786.600
01/07/2015 138,54 138,71 135,81 136,73 -0,04% 2,09% 839.300
30/06/2015 134,29 137,24 133,47 136,78 +3,38% 2,81% 1.269.000
29/06/2015 133,70 136,29 131,57 132,31 -1,88% 3,53% 1.583.400
26/06/2015 135,52 135,99 132,85 134,84 -0,38% 2,32% 1.227.500
25/06/2015 136,66 137,38 133,78 135,36 -0,83% 2,63% 932.600
24/06/2015 138,85 139,87 136,00 136,49 -1,71% 2,79% 1.249.800
23/06/2015 141,04 141,51 137,16 138,86 -0,81% 3,08% 1.198.500
22/06/2015 138,79 140,32 137,28 140,00 +1,50% 2,19% 1.253.500
19/06/2015 137,21 138,65 135,07 137,93 -0,53% 2,61% 2.013.100
18/06/2015 132,27 140,49 132,21 138,66 +12,18% 6,26% 5.642.100
17/06/2015 121,80 123,99 121,58 123,60 +2,06% 1,98% 1.183.700
16/06/2015 122,00 122,98 120,79 121,10 -0,68% 1,80% 800.300
15/06/2015 121,30 122,60 120,01 121,93 -0,08% 2,14% 809.200
12/06/2015 122,30 122,79 121,21 122,03 -0,82% 1,29% 763.100
11/06/2015 122,81 123,49 121,80 123,04 +0,63% 1,38% 678.400
10/06/2015 120,92 122,41 117,54 122,27 +1,33% 4,03% 1.030.000
09/06/2015 123,47 124,48 120,21 120,66 -2,62% 3,46% 1.300.500
08/06/2015 125,00 125,58 122,96 123,90 +0,04% 2,10% 834.000
05/06/2015 121,65 124,25 119,66 123,85 +2,81% 3,77% 1.013.200
04/06/2015 122,61 123,78 118,98 120,46 -2,67% 3,91% 1.130.800
03/06/2015 124,12 125,59 122,96 123,77 -0,19% 2,12% 781.100
02/06/2015 123,77 125,21 120,86 124,01 -0,02% 3,51% 1.082.800
01/06/2015 125,70 126,92 121,86 124,03 -1,23% 4,03% 1.181.300
29/05/2015 127,73 127,82 124,20 125,57 -1,43% 2,83% 1.650.600
28/05/2015 129,43 130,00 126,33 127,39 -1,66% 2,84% 1.184.300